286 related articles for article (PubMed ID: 23359050)
1. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Neumann M; Coskun E; Fransecky L; Mochmann LH; Bartram I; Sartangi NF; Heesch S; Gökbuget N; Schwartz S; Brandts C; Schlee C; Haas R; Dührsen U; Griesshammer M; Döhner H; Ehninger G; Burmeister T; Blau O; Thiel E; Hoelzer D; Hofmann WK; Baldus CD
PLoS One; 2013; 8(1):e53190. PubMed ID: 23359050
[TBL] [Abstract][Full Text] [Related]
2. The Clinical and Molecular Characteristics of FLT3 Mutations in Chinese De Novo Adolescent and Adult Acute Lymphoblastic Leukemia Patients.
Shen Z; Chu XL; Wang RX; Li JL; Liu MY; Xie YY; Wang C; Han R; Yu JQ; Wang J; Tao T; Shen HJ; Chen SN; Wu DP; Qiu QC; Liu SB; Xue SL
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e259-e269. PubMed ID: 32173273
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations.
Neumann M; Heesch S; Gökbuget N; Schwartz S; Schlee C; Benlasfer O; Farhadi-Sartangi N; Thibaut J; Burmeister T; Hoelzer D; Hofmann WK; Thiel E; Baldus CD
Blood Cancer J; 2012 Jan; 2(1):e55. PubMed ID: 22829239
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.
Noronha EP; Andrade FG; Zampier C; de Andrade CF; Terra-Granado E; Pombo-de-Oliveira MS;
Blood Cells Mol Dis; 2016 Mar; 57():74-80. PubMed ID: 26852660
[TBL] [Abstract][Full Text] [Related]
5. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.
Neumann M; Heesch S; Schlee C; Schwartz S; Gökbuget N; Hoelzer D; Konstandin NP; Ksienzyk B; Vosberg S; Graf A; Krebs S; Blum H; Raff T; Brüggemann M; Hofmann WK; Hecht J; Bohlander SK; Greif PA; Baldus CD
Blood; 2013 Jun; 121(23):4749-52. PubMed ID: 23603912
[TBL] [Abstract][Full Text] [Related]
6. Distinct immunophenotype of early T-cell progenitors in T lymphoblastic leukemia/lymphoma may predict FMS-like tyrosine kinase 3 mutations.
Zaremba CM; Oliver D; Cavalier M; Fuda F; Karandikar NJ; Chen W
Ann Diagn Pathol; 2012 Jan; 16(1):16-20. PubMed ID: 22050963
[TBL] [Abstract][Full Text] [Related]
7. Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia.
Ye MT; Wang Y; Zuo Z; Calin S; He H; Tang Z; Jabbour EJ; Borthakur G; Zhang Y; Yang Y; You MJ
Cancer; 2023 Jan; 129(1):49-59. PubMed ID: 36281717
[TBL] [Abstract][Full Text] [Related]
8. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia.
Hoehn D; Medeiros LJ; Chen SS; Tian T; Jorgensen JL; Ahmed Y; Lin P
Am J Clin Pathol; 2012 Feb; 137(2):213-9. PubMed ID: 22261446
[TBL] [Abstract][Full Text] [Related]
9. BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
Kawashima-Goto S; Imamura T; Tomoyasu C; Yano M; Yoshida H; Fujiki A; Tamura S; Osone S; Ishida H; Morimoto A; Kuroda H; Hosoi H
PLoS One; 2015; 10(7):e0132926. PubMed ID: 26172269
[TBL] [Abstract][Full Text] [Related]
10. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
11. Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL.
Lhermitte L; Ben Abdelali R; Villarèse P; Bedjaoui N; Guillemot V; Trinquand A; Libura M; Bedin AS; Petit A; Dombret H; Leverger G; Ifrah N; Hermine O; Macintyre E; Asnafi V
Leukemia; 2013 Feb; 27(2):305-14. PubMed ID: 22751451
[TBL] [Abstract][Full Text] [Related]
12. FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.
Loschi M; Sammut R; Chiche E; Cluzeau T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070902
[TBL] [Abstract][Full Text] [Related]
13. BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients.
Kraszewska MD; Dawidowska M; Kosmalska M; Sędek L; Grzeszczak W; Kowalczyk JR; Szczepański T; Witt M;
Blood Cells Mol Dis; 2013 Jan; 50(1):33-8. PubMed ID: 23040356
[TBL] [Abstract][Full Text] [Related]
14. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
Khogeer H; Rahman H; Jain N; Angelova EA; Yang H; Quesada A; Ok CY; Sui D; Wei P; Al Fattani A; Pierce S; Loghavi S; Lamb A; Hu P; Thakral B; Kanagal-Shamanna R; Jorgensen JL; Jabbour EJ; Kantarjian HM; Medeiros LJ; Khoury JD
Br J Haematol; 2019 Aug; 186(4):538-548. PubMed ID: 31115909
[TBL] [Abstract][Full Text] [Related]
15. T-lymphoid/myeloid mixed phenotype acute leukemia and early T-cell precursor lymphoblastic leukemia similarities with
Noronha EP; Marques LVC; Andrade FG; Sardou-Cezar I; Dos Santos-Bueno FV; Zampier CDP; Terra-Granado E; Pombo-de-Oliveira MS
Cancer Manag Res; 2019; 11():3933-3943. PubMed ID: 31118806
[No Abstract] [Full Text] [Related]
16. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
17. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
Kiyoi H; Naoe T
Int J Hematol; 2006 May; 83(4):301-8. PubMed ID: 16757428
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
19. Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.
Fransecky L; Neumann M; Heesch S; Schlee C; Ortiz-Tanchez J; Heller S; Mossner M; Schwartz S; Mochmann LH; Isaakidis K; Bastian L; Kees UR; Herold T; Spiekermann K; Gökbuget N; Baldus CD
J Hematol Oncol; 2016 Sep; 9(1):95. PubMed ID: 27658391
[TBL] [Abstract][Full Text] [Related]
20. Optimized outcome prediction of oncogenetic mutations in non-early T-cell precursor acute lymphoblastic leukemia.
Peng LJ; Wang SS; Guo SS; Zhang JJ; Liu YF; Rousseaux S; Khochbin S; Chen B; Wang J; Mi JQ
Immunobiology; 2022 May; 227(3):152205. PubMed ID: 35279479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
